Search results | bms

Reports

Sorry, your search returned no results.


Insights

Sanofi & BMS re-negotiate pharma partnering agreement for marketing Plavix and Avapro

Sanofi and Bristol-Myers Squibb Company have restructured their successful long-term pharma partnering alliance following the loss of exclusivity of Plavix and Avapro/Avalide in many major markets

Amylin snagged in $5.3 billion BMS/AZ big pharma pincer movement

In an novel big pharma partnership, Bristol-Myers Squibb has snapped up Amylin for $5.3 billion whilst simultaneously collaborating with AstraZeneca to off-load Amylin’s diabetes portfolio for $3.4 billion

Amylin on lookout for buyers after rejecting bid from big pharma BMS

Amylin Pharmaceuticals, the maker of the diabetes drugs Bydureon and Byetta, is seeking a buyer after rejecting an unsolicited bid from big pharma Bristol-Myers Squibb, two people with knowledge of the matter said

Dealmakers weekly review – January 9 2012 – Boehringer, Forma, Ironwood, Bionoics, BMS, Inhibitex

The first week of 2012 has started with a rash of deals being announced across the industry.

BMS snaps up Inhibitex for $2.5 billion for hep C portfolio

2012 started with quite a bang with this weekend’s announcement that Bristol-Myers Squibb has agreed to acquire Inhibitex for a hefty $2.5 billion

Flush with cash, BMS chief confirms ‘100% pharma’ focus

The Chief Executive of Bristol-Myers Squibb Co said the company intends to remain “100 percent” in prescription medicines and is prepared to use its $10 billion cash hoard to gain new drugs through moderate size deals with other drugmakers.

BMS tipped as potential takeover target

Bristol-Myers Squibb’s prospects are brightening as a takeover target both in regards to recent upbeat drug news and because of its late-stage pipeline, according to the equity research shop at Jefferies.

Making contact – with Big Pharma

CP Insight > Insight Toolkit > Finding Partners > Making contact – with Big Pharma Making the right entry point into a bigpharma company is critical in ensuring your information does not end up going into a black hole. Increasingly in recent years bigpharma has come to realize the importance of partnering to the development of a robust product pipeline. As a more »

Bristol-Myers Squibb

Bristol-Myers Squibb (BMS) is a top pharmaceutical company based in New York, NY, USA.

Will Allergan join Valeant’s list of acquisitions?

Allergan is currently the subject of much speculation as Valeant Pharmaceuticals looks to acquire it. Valeant Pharmaceuticals, well known for building its company via acquisitions, put in a $46 billion bid one week ago to acquire Californian based botox maker Allergan.

Events

Sorry, your search returned no results.


Deals

Lilly snags rights to Erbitux from BMS

Eli Lilly and Bristol-Myers Squibb announced that the companies have agreed to transfer rights to Erbitux (cetuximab) in North America

BMS and UniQure in $1bn gene therapy pact

Agreement provides Bristol-Myers Squibb with exclusive access to uniQure’s gene therapy technology platform for multiple targets in cardiovascular diseases

Zai licenses Brivanib from BMS

Bristol-Myers Squibb and ZAI Lab have signed a definitive agreement

BMS and Bavarian Nordic in Prostvac licensing pact

Bavarian Nordic and Bristol-Myers Squibb announced an exclusive option to license and commercialize PROSTVAC

BMS and Rigel ink cancer immunotherapies pact

Rigel Pharmaceuticals and Bristol-Myers Squibb have entered into a collaboration agreement for the discovery, development and commercialization of cancer immunotherapies

BMS acquires Flexus Biosciences in $1.25 billion deal

Bristol-Myers Squibb will acquire all of the outstanding capital stock of Flexus

Eli Lilly and BMS study Opdivo combined with galunisertib

Bristol-Myers Squibb and Eli Lilly announced a clinical trial collaboration to evaluate the safety, tolerability and preliminary efficacy of Bristol-Myers Squibb’s immunotherapy Opdivo (nivolumab) in combination with Lilly’s galunisertib

BMS and Seattle evaluate Adcetris and Opdivo combination

Seattle Genetics and Bristol-Myers Squibb have entered into a clinical trial collaboration agreement to evaluate the investigational combination of Seattle Genetics’ antibody-drug conjugate (ADC) Adcetris (brentuximab vedotin) and Bristol-Myers Squibb’s immunotherapy Opdivo (nivolumab) in two planned Phase 1/2 clinical trials

BMS and Calibr in small molecule anti-fibrotic pact

Bristol-Myers Squibb and the California Institute for Biomedical Research (Calibr) announced have entered into a worldwide research collaboration to develop novel small molecule anti-fibrotic therapies

BMS, Ono, Kyowa in nivolumab-ogamulizumab clinical evaluation

Ono Pharmaceutical, Bristol-Myers Squibb Company and Kyowa Hakko Kirin have entered into a clinical trial collaboration agreement to conduct a Phase 1 combination study